Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5466849 | 0.91 | RAB9A (0.38) | RAB9AKMT2ASMN1; SMN2NPC1TP53 | |
| SCHEMBL5947394 | 0.80 | RAB9A (0.38) | RAB9AKMT2ASMN1; SMN2NPC1TP53 | |
| SCHEMBL5490458 | 0.79 | RAB9A (0.39) | RAB9AKMT2ASMN1; SMN2NPC1TP53 | |
| SCHEMBL12450805 | 0.79 | RAB9A (0.39) | RAB9AKMT2ASMN1; SMN2NPC1TP53 | |
| SCHEMBL5349668 | 0.79 | RAB9A (0.39) | RAB9AKMT2ASMN1; SMN2NPC1TP53 | |
| SCHEMBL4456444 | 0.79 | RAB9A (0.39) | RAB9AKMT2ASMN1; SMN2NPC1TP53 | |
| SCHEMBL12914592 | 0.78 | RAB9A (0.40) | RAB9AKMT2ASMN1; SMN2NPC1TP53 | |
| SCHEMBL12450810 | 0.78 | RAB9A (0.40) | RAB9AKMT2ASMN1; SMN2NPC1TP53 | |
| SCHEMBL5703664 | 0.76 | KMT2A (0.39) | RAB9AKMT2ASMN1; SMN2NPC1TP53 | |
| SCHEMBL19677629 | 0.76 | PSMB8 (0.40) | RAB9AKMT2ASMN1; SMN2NPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662849-B2 | Amidino compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20070276019-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20060264464-A1 | Amidino compounds as cysteine protease inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2006-11-23 | — | — | US | disclosed |
| US-7091360-B2 | Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof | AVENTIS PHARMA S.A. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060135781-A1 | Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof | AVENTIS PHARMACEUTICALS, INC. | 2006-06-22 | — | — | US | disclosed |
| US-20040019218-A1 | Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof | AXYS PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019218-A1 | Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof | SPINT2, CTSV, CTSZ | RAB9A 3107/4885KMT2A 2891/4885SMN1; SMN2 4740/4885 |
| US-20060264464-A1 | Amidino compounds as cysteine protease inhibitors | CTSF, CTSB, CTSS | RAB9A 966/4885KMT2A 4394/4885SMN1; SMN2 4478/4885 |
| US-20060135781-A1 | Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof | SPINT2, CTSV, CTSZ | RAB9A 3107/4885KMT2A 2891/4885SMN1; SMN2 4740/4885 |
| US-20070276019-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | CTSF, CTSS, CTSE | RAB9A 978/4885KMT2A 4029/4885SMN1; SMN2 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.